BACKGROUND: African Americans (AAs) and Latinos in United States bear a disproportionate burden of HIV infection, yet remain underrepresented in HIV vaccine trials. The success in engaging and enrolling AAs and Latinos in phase 1 and phase 2 vaccine trials at 2 research sites in New York City is described. METHODS: A retrospective analysis of 1683 HIV-uninfected individuals who completed > or = 1 stage of the screening process from 2002 to 2006. Data on sociodemographic, behavioral characteristics, medical eligibility, and enrollment in National Institutes of Health-sponsored vaccine trials were collected. RESULTS: 7.5% of screening participants completed enrollment; 33% were AAs, 24% Latinos. The proportion of enrollees did not differ significantly by race/ethnicity. Low-risk vs. high-risk AAs (49% vs. 23%, P = 0.006) and high-risk vs. low-risk Latinos (31% vs. 13%, P = 0.006) were more likely to enroll. Among them, loss to follow-up was the most common reason for not completing screening. In multivariate analysis, older participants, high-risk men, and high-risk women were more likely to complete enrollment. CONCLUSIONS: Once potential minority participants are identified and engaged in the screening process, it is possible to enroll them at rates comparable to white participants. Experience at these sites suggests that the challenge in achieving high rates of minority participation is in increasing the initial pool of candidates prescreening for HIV vaccine studies.
BACKGROUND: African Americans (AAs) and Latinos in United States bear a disproportionate burden of HIV infection, yet remain underrepresented in HIV vaccine trials. The success in engaging and enrolling AAs and Latinos in phase 1 and phase 2 vaccine trials at 2 research sites in New York City is described. METHODS: A retrospective analysis of 1683 HIV-uninfected individuals who completed > or = 1 stage of the screening process from 2002 to 2006. Data on sociodemographic, behavioral characteristics, medical eligibility, and enrollment in National Institutes of Health-sponsored vaccine trials were collected. RESULTS: 7.5% of screening participants completed enrollment; 33% were AAs, 24% Latinos. The proportion of enrollees did not differ significantly by race/ethnicity. Low-risk vs. high-risk AAs (49% vs. 23%, P = 0.006) and high-risk vs. low-risk Latinos (31% vs. 13%, P = 0.006) were more likely to enroll. Among them, loss to follow-up was the most common reason for not completing screening. In multivariate analysis, older participants, high-risk men, and high-risk women were more likely to complete enrollment. CONCLUSIONS: Once potential minority participants are identified and engaged in the screening process, it is possible to enroll them at rates comparable to white participants. Experience at these sites suggests that the challenge in achieving high rates of minority participation is in increasing the initial pool of candidates prescreening for HIV vaccine studies.
Authors: Edward Mills; Curtis Cooper; Gordon Guyatt; Amy Gilchrist; Beth Rachlis; Chris Sulway; Kumanan Wilson Journal: AIDS Date: 2004-11-19 Impact factor: 4.177
Authors: Jacqueline M O'Connell; Robert S Hogg; Keith Chan; Steffanie A Strathdee; Nancy McLean; Steve L Martindale; Brian Willoughby; Robert Remis Journal: J Acquir Immune Defic Syndr Date: 2002-12-15 Impact factor: 3.731
Authors: Mary A Allen; Thomas S Liang; Thomas La Salvia; Brian Tjugum; Robert J Gulakowski; Matthew Murguía Journal: J Acquir Immune Defic Syndr Date: 2005-12-15 Impact factor: 3.731
Authors: Gaston Djomand; Joanna Katzman; Dante di Tommaso; Michael G Hudgens; George W Counts; Beryl A Koblin; Patrick S Sullivan Journal: Public Health Rep Date: 2005 Sep-Oct Impact factor: 2.792
Authors: R P Strauss; S Sengupta; S Kegeles; E McLellan; D Metzger; S Eyre; F Khanani; C B Emrick; K M MacQueen Journal: J Acquir Immune Defic Syndr Date: 2001-01-01 Impact factor: 3.731
Authors: David C Montefiori; Marcus Altfeld; Paul K Lee; Miroslawa Bilska; Jintao Zhou; Mary N Johnston; Feng Gao; Bruce D Walker; Eric S Rosenberg Journal: J Immunol Date: 2003-04-01 Impact factor: 5.422
Authors: H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: Amina P Alio; Sheldon D Fields; Damon L Humes; Catherine A Bunce; Stephaun E Wallace; Cindi Lewis; Heather Elder; Steven Wakefield; Michael C Keefer Journal: J Gay Lesbian Soc Serv Date: 2014-07-01
Authors: Carrie J Sopher; Blythe Jane S Adamson; Michele P Andrasik; Danna M Flood; Steven F Wakefield; David M Stoff; Ryan S Cook; James G Kublin; Jonathan D Fuchs Journal: Am J Public Health Date: 2014-08-14 Impact factor: 9.308
Authors: Stefanie L Russell; Ralph V Katz; Min Qi Wang; Ryan Lee; B Lee Green; Nancy R Kressin; Cristina Claudio Journal: HIV Clin Trials Date: 2011 Jan-Feb
Authors: Tanya M Ellman; Kellie Hawkins; Jorge Benitez; Ramon Negron; Steven Chang; Steven Palmer; Verna Robertson; Mary Ann Chiasson; Magdalena E Sobieszczyk Journal: Vaccine Date: 2015-10-11 Impact factor: 3.641